Optimizing treatment of chronic myeloid leukemia: A rational approach

Oncologist

Volumn 9, Issue 3, 2004, Pages 259-270

  Stone, Richard M ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Antineoplastic agents; Imatinib; Interferon alfa; Leukemia, myeloid, chronic; Stem cell transplantation

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; BUSULFAN; CYTARABINE; HOMOHARRINGTONINE; HYDROXYUREA; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; ALGORITHM; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALOPECIA; ANASARCA; ASCITES; BONE MARROW HYPOPLASIA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHILL; CHRONIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTINUING EDUCATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG FEVER; EDEMA; FATIGUE; FEVER; FLU LIKE SYNDROME; GANGRENE; GASTROINTESTINAL TOXICITY; GRAFT VERSUS HOST REACTION; HEADACHE; HEART ARRHYTHMIA; HEART MUSCLE FIBROSIS; HLA MATCHING; HUMAN; HYPOTENSION; INSOMNIA; LEG ULCER; LICHENOID ERUPTION; LIVER FIBROSIS; LUNG EDEMA; LUNG FIBROSIS; LUNG TOXICITY; MAJOR CLINICAL STUDY; MUSCLE CRAMP; MYALGIA; NAUSEA; NEUROTOXICITY; ONCOLOGY; PERICARDIAL EFFUSION; PLEURA EFFUSION; PRIORITY JOURNAL; RASH; REVIEW; SKIN ATROPHY; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; VASCULITIS; VOMITING; WEIGHT REDUCTION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; HUMANS; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC; PIPERAZINES; PYRIMIDINES; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 2942593704     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.9-3-259     Document Type: Review

References (88)

1. Fialkow PJ, Jacobson RJ, Papayannopoulou T. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am J Med 1977;63:125-130.
2. Druker BJ, Tamura S, Buchdunger E et al. Effects of a selective inhibitor of the Abl tyrosine kinase on growth of Bcr-Abl positive cells. Nat Med 1996;2:561-566.
3. Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999;340:1330-1340.
4. Silver RT, Woolf SH, Hehlmann R et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 1999;94:1517-1536.
5. Nowell P, Hungerford D. A minute chromosome in human chronic granulocytic leukemia. Science 1960;132:1947.
6. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining (letter). Nature 1973;243:290-293.
7. Heisterkamp N, Jenster G, ten Hoeve J et al. Acute leukaemia in bcr/abl transgenic mice. Nature 1990;344:251-253.
8. Kelliher MA, McLaughlin J, Witte ON et al. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci USA 1990;87:6649-6653.
9. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990;247:824-830.
10. Hehlmann R, Heimpel H, Hasford J et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood 1994;84:4064-4077.
11. Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994;330:820-825.
12. Hensley ML, Peterson B, Silver RT et al. Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: analysis of Cancer and Leukemia Group B 9013. J Clin Oncol 2000;18:1301-1308.
13. Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1037.
14. Druker BJ, Sawyers CL, Kantarjian H et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-1042.
15. Kantarjian H, Sawyers C, Hochhaus A et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645-652.
16. Talpaz M, Silver RT, Druker BJ et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002;99:1928-1937.
17. Sawyers CL, Hochhaus A, Feldman E et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002;99:3530-3539.
18. O'Brien SG, Guilhot F, Larson RA et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
19. Peggs K, Mackinnon S. Imatinib mesylate-the new gold standard for treatment of chronic myeloid leukemia. N Engl J Med 2003;348:1048-1050.
20. Clift RA, Storb R. Marrow transplantation for CML: the Seattle experience. Bone Marrow Transplant 1996;17(suppl 3):S1-S3.
21. Horowitz MM, Rowlings PA, Passweg JR. Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant 1996;17(suppl 3):S5-S6.
22. van Rhee F, Szydlo RM, Hermans J. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1997;20:553-560.
23. Giralt S, Szydlo R, Goldman JM et al. Effect of short-term interferon therapy on the outcome of subsequent HLA-identical sibling bone marrow transplantation for chronic myelogenous leukemia: an analysis from the International Bone Marrow Transplant Registry. Blood 2000;95:410-415.
24. Ohnishi K, Ino T, Kishimoto Y et al. Multicenter prospective study of interferon-alpha versus bone marrow transplantation for newly diagnosed patients with chronic myelogenous leukemia: a preliminary analysis. Cancer Chemother Pharmacol 2001;48(suppl 1):S59-S64.
25. Gaziev D, Galimberti M, Polchi P et al. Fate of chronic myeloid leukemia patients treated with allogeneic bone marrow transplantation or chemotherapy and/or interferon at a single center: long-term results. Bone Marrow Transplant 2002;29:1-8.
26. Cwynarski K, Roberts IA, Iacobelli S et al. Stem cell transplantation for chronic myeloid leukemia in children. Blood 2003;102:1224-1231.
27. Radich JP, Gooley T, Bryant E et al. The significance of bcr-abl molecular detection in chronic myeloid leukemia patients "late," 18 months or more after transplantation. Blood 2001;98:1701-1707.
28. Gratwohl A, Hermans J. Allogeneic bone marrow transplantation for chronic myeloid leukemia. Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1996;17(suppl 3):S7-S9.
29. Gratwohl A, Hermans J, Goldman JM et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998;352:1087-1092.
30. Clift RA, Radich J, Appelbaum FR et al. Long-term follow-up of a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide for patients receiving allogeneic marrow transplants during chronic phase of chronic myeloid leukemia. Blood 1999;94:3960-3962.
31. Clift RA, Buckner CD, Thomas ED et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 1994;84:2036-2043.
32. Slattery JT, Clift RA, Buckner CD et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 1997;89:3055-3060.
33. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995;86:2041-2050.
34. Porter DL, Antin JH. Infusion of donor peripheral blood mononuclear cells to treat relapse after transplantation for chronic myelogenous leukemia. Hematol Oncol Clin North Am 1998;12:123-150.
35. Hansen JA, Gooley TA, Martin PJ et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 1998;338:962-968.
36. Weisdorf DJ, Anasetti C, Antin JH et al. Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood 2002;99:1971-1977.
37. Nevill TJ, Barnett MJ, Klingemann HG et al. Regimen-related toxicity of a busulfan-cyclophosphamide conditioning regimen in 70 patients undergoing allogeneic bone marrow transplantation. J Clin Oncol 1991;9:1224-1232.
38. Or R, Shapira MY, Resnick I et al. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 2003;101:441-445.
39. Hehlmann R, Heimpel H, Hasford J et al. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group. Blood 1993;82:398-407.
40. Kantarjian HM, Giles FJ, O'Brien S et al. Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy. Hematol Oncol Clin North Am 1998;12:31-80.
41. Benelux CML Study Group. Randomized study on hydroxyurea alone versus hydroxyurea combined with low-dose interferon-α2b for chronic myeloid leukemia. Blood 1998;91:2713-2721.
42. Sandhu HS, Barnes PJ, Hernandez P. Hydroxyurea-induced hypersensitivity pneumonitis: a case report and literature review. Can Respir J 2000;7:491-495.
43. Vassallo C, Passamonti F, Merante S et al. Muco-cutaneous changes during long-term therapy with hydroxyurea in chronic myeloid leukemia. Clin Exp Dermatol 2001;26:141-148.
44. Daoud MS, Gibson LE, Pittelkow MR. Hydroxyurea dermopathy: a unique lichenoid eruption complicating long-term therapy with hydroxyurea. J Am Acad Dermatol 1997;36:178-182.
45. Cox C, Nowicky D, Young R. Hydroxyurea-related ankle ulcers in patients with myeloproliferative disorders: a case report and review of the literature. Ann Plast Surg 1997;39:546-549.
46. Weinlich G, Schuler G, Greil R et al. Leg ulcers associated with long-term hydroxyurea therapy. J Am Acad Dermatol 1998;39:372-374.
47. Kato N, Kimura K, Yasukawa K et al. Hydroxyurea-related leg ulcers in a patient with chronic myelogenous leukemia: a case report and review of the literature. J Dermatol 1999;26:56-62.
48. Poros A, Nadasdy K. Leg ulcer in hydroxyurea-treated patients. Haematologia (Budap) 2000;30:313-318.
49. Tarumoto T, Imagawas, S, Hotta T et al. A case of bilateral heel ulcers associated with hydroxyurea therapy for chronic myelogenous leukemia. Jpn J Clin Oncol 2000;30:159-162.
50. Kawabata H, Kamada T, Takatsuka Y et al. Successful treatment for leg ulcers due to hydroxyurea in a patient with chronic myelogenous leukaemia. Haematologia (Budap) 2002;31:369-372.
51. De Simone C, Guerriero C, Guidi B et al. Multiple squamous cell carcinomas of the skin during long-term treatment with hydroxyurea. Eur J Dermatol 1998;8:114-115.
52. Leo E, Kramer A, Hochhaus A et al. Gangrene of the toes in a patient with chronic myelogenous leukemia after long-term hydroxyurea therapy. Ann Hematol 2002;81:467-469.
53. Paydas S, Zorludemir S, Sahin B. Vasculitis and leukemia. Leuk Lymphoma 2000;40:105-112.
54. Jackson GH, Wallis J, Ledingham J et al. Hydroxyurea-induced acute alveolitis in a patient with chronic myeloid leukaemia. Cancer Chemother Pharmacol 1990;27:168-169.
55. Kantarjian HM, Talpaz M, Santini V et al. Homoharringtonine: history, current research, and future direction. Cancer 2001;92:1591-1605.
56. Kantarjian HM, Talpaz M, Smith TL et al. Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia. J Clin Oncol 2000;18:3513-3521.
57. Talpaz M, Kantarjian HM, McCredie KB et al. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med 1986;314:1065-1069.
58. Talpaz M, Kantarjian HM, Kurzrock R et al. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia: Philadelphia chromosome-positive patients. Ann Intern Med 1991;114:532-538.
59. Ozer H, George SL, Schiffer CA et al. Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B Study 8583. Blood 1993;82:2975-2984.
60. Allan NC, Richards SM, Shepherd PC. UK Medical Research Council randomised trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. Lancet 1995;345:1392-1397.
61. Ohnishi K, Ohno R, Tomonaga M et al. A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 1995;86:906-916.
62. Guilhot F, Chastang C, Michallet M et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med 1997;337:223-229.
63. Kantarjian HM, O'Brien S, Cortes JE et al. Complete cytogenetic and molecular responses to interferon-α-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer 2003;97:1033-1041.
64. Kantarjian HM, Smith TL, O'Brien S et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service. Ann Intern Med 1995;122:254-261.
65. Baccarani M, Russo D, Rosti G et al. Interferon-alfa for chronic myeloid leukemia. Semin Hematol 2003;40:22-33.
66. Faderl S, Talpaz M, Estrov Z et al. The biology of chronic myeloid leukemia. N Engl J Med 1999;341:164-172.
67. Cortes J, Giles F, O'Brien S et al. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alfa. Blood 2003;102:83-86.
68. Kantarjian HM, Talpaz M, O'Brien S et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 2003;101:473-475.
69. Deininger MW, O'Brien SG, Ford JM et al. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 2003;21:1637-1647.
70. Hahn EA, Glendenning GA, Sorensen MV et al. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS study. J Clin Oncol 2003;21:2138-2146.
71. Hughes TP, Kaeda J, Branford S et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003;349:1423-1432.
72. Hochhaus A, Reiter A, Saussele S et al. Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. Blood 2000;95:62-66.
73. Kantarjian H, Talpaz M, O'Brien S et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004;103:2873-2878.
74. Gorre ME, Mohammed M, Ellwood K et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-880.
75. von Bubnoff N, Schneller F, Peschel C et al. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 2002;359:487-491.
76. Branford S, Rudzki Z, Walsh S et al. High frequency of point mutations clustered within the adenosine-triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002;99:3472-3475.
77. le Coutre P, Tassi E, Varella-Garcia M et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000;95:1758-1766.
78. Mahon FX, Deininger MW, Schultheis B et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000;96:1070-1079.
79. Branford S, Rudzki Z, Walsh S et al. Detection of bcr-abl mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003;102:276-283.
80. Corbin AS, La Rosee, Stoffregen EP et al. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 2003;101:4611-4614.
81. Roumiantsev S, Shah NP, Gorre ME et al. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci USA 2002;99:10700-10705.
82. Deininger MW, Druker BJ. Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev 2003;55:401-423.
83. Hochhaus A, Kreil S, Corbin AS et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002;16:2190-2196.
84. + leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst 2000;92:1641-1650.
85. Italian Cooperative Study Group on Chronic Myeloid Leukemia. Long-term follow-up of the Italian trial of interferon-α versus conventional chemotherapy in chronic myeloid leukemia. Blood 1998;92:1541-1548.
86. Druker BJ. STI571 (Gleevec®/Glivec®, imatinib) versus interferon (IFN) + cytarabine as initial therapy for patients with CML: results of a randomized study. Proc Am Soc Clin Oncol 2002;21:1a.
87. + chronic myeloid leukemia (CML): results of a randomized phase III study vs interferon-alfa + cytarabine (IFN + AraC). Blood 2002;100:4a.
88. Champlin RE, Schmitz N, Horowitz MM et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. Blood 2000;95:3702-3709.